ETC-216 - Phospholipid Therapy for Coronary Heart Disease (CHD) Patients
Key Data:
Drug (brand/generic) ETC-216
ETC-216
Company/licensee
Esperion Therapeutics / Pfizer
Therapy class
Phospholipid
Product description
Synthetic variant of HDL
Current indication
Treatment of atherosclerosis
Market sector
CVD
Development status
Phase II
